Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11992531 C

Patent 11992531 was granted and assigned to C4 Therapeutics on May, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

C4 Therapeutics

0

Current Assignee

C4 Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Christopher G. Nasveschuk0

Gesine Kerstin Veits0

James A. Henderson0

Kiel Lazarski0

Minsheng He0

Andrew J. Phillips0

Harit U. Vora0

Yanke Liang0

Date of Patent

May 28, 2024

0

Patent Application Number

171077810

Date Filed

November 30, 2020

0

Patent Citations

US Patent 9249161 Bromodomain inhibitors and uses thereof

0

US Patent 7041298 Proteolysis targeting chimeric pharmaceutical

0

US Patent 7208157 Proteolysis targeting chimeric pharmaceutical

0

US Patent 9125915 Antitumor agent

0

US Patent 10351568 Compositions and methods for enhancing proteasome activity

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

0

Patent abstract

This invention provides Degronimers that have carbon-linked E3 Ubiquitin Ligase targeting moieties (Degrons), which can be linked to a targeting ligand for a protein that has been selected for in vivo degradation, and methods of use and compositions thereof as well as methods for their preparation.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11992531 C

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool